Get started
Author

Lorenzo Corsi

Observed institution: AULSS 2 Marca Trevigiana
ORCID: 0000-0002-4574-8675
Observed ORCID: 0000-0002-4574-8675
OpenAlex ID: A5075379139
Comparison between clinical trials and real-world evidence studies on biologics for severe asthma
2022 · Francesco Menzella, Andrea Ballarin, et al. · Journal of International Medical Research · 23
A real-world study on tezepelumab effectiveness in severe asthma focusing on small airway dysfunction
2025 · Francesco Menzella, Marcello Cottini, et al. · Respiratory Medicine · 16
Oscillometry in severe asthma: the state of the art and future perspectives
2023 · Francesco Menzella, Leonardo Antonicelli, et al. · Expert Review of Respiratory Medicine · 13
Tezepelumab Improves Small Airways Dysfunction in Severe Asthma: A 52‐Week Real‐World Study
2026 · Francesco Menzella, Marcello Cottini, et al. · Clinical and Translational Allergy · 8
PDF
Severe hypereosinophilia in a patient treated with dupilumab and shift to mepolizumab: the importance of multidisciplinary management. A case report and literature review
2024 · Sara Munari, Giulia Ciotti, et al. · Drugs in Context · 8
PDF
Tezepelumab: patient selection and place in therapy in severe asthma
2024 · Francesco Menzella, Sara Munari, et al. · Journal of International Medical Research · 5
Real-world effectiveness of tezepelumab on clinical remission and small airway dysfunction in severe asthma: a 52-week prospective study
2026 · Francesco Menzella, Rory Chan, et al. · Expert Opinion on Biological Therapy · 2
Dual Remission in Patients with Moderate-to-Severe Asthma and CRSwNP Treated with Dupilumab: A 24-Month Real-World Study
2026 · Francesco Menzella, Alvise Berti, et al. · Journal of Clinical Medicine · 2
PDF
Tezepelumab for early-onset severe allergic asthma with persistent airflow limitation and small airway dysfunction: a treatable traits approach
2025 · Francesco Menzella, Claudio Sorino, et al. · Drugs in Context · 2
PDF
Switching from multiple-inhaler triple therapy to single,extra fine-inhaler triple therapy in severe refractory asthma with EGPA: beyond control. Case report and review of the literature
2025 · Francesco Menzella, Marcello Cottini, et al. · Drugs in Context · 2
PDF
Sustained clinical remission over 24 months with tezepelumab in real-world severe uncontrolled asthma
2026 · Francesco Menzella, Corrado Pelaia, et al. · Annals of Allergy Asthma & Immunology
Dual REmission in moderate-to-severe AsthMa and Nasal Polyps: a multicentric observational Phase IV real-life study (DREAM-NP)
2026 · Francesco Menzella, Eugenio De Corso, et al. · Figshare
Real-world effectiveness of tezepelumab on clinical remission and small airway dysfunction in severe asthma: a 52-week prospective study
2026 · Francesco Menzella, Rory Chan, et al. · Figshare
Works count: 13
Citation count: 81
H-index: 5
I10-index: 3
Year
Topic
Type